TB-500 (5 mg)

Thymosin Beta-4 Synthetic Analogue: 43-amino acid peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH); N-terminal acetylation for enhanced metabolic stability; ≥98% purity by HPLC; 2,000+ peer-reviewed publications
Multi-Pathway Research Profile: G-actin sequestration (Kd 0.5–0.7 μM, conserved ¹⁷LKKTETQ²³ binding domain), VEGF upregulation via Wnt/β-catenin/Lef-1, PI3K/Akt/eNOS pathway, NF-κB inhibition, TGF-β1 suppression
Active Research Domains: Angiogenesis and vascular biology, cardiovascular tissue research, neuroprotection models, pulmonary and hepatic fibrosis, actin cytoskeletal dynamics; supplied as lyophilized powder for in vitro research

Manufacturer: RiboCore

Availability: 99 in stock

SKU: RP-TB-5MG

$39.00

Ship to

Shipping Method

Estimated Delivery

Price

No shipping options

Technical Specifications

Characteristic	Value
CAS Number	77591-33-4
Molecular Weight	4963.51 Da (acetate form)
Molecular Formula	C₂₁₂H₃₅₀N₅₆O₇₈S
Purity	≥98% (HPLC)
Form	Lyophilized powder
Sequence Length	43 amino acids (N-terminal acetylation)

TB-500 (Thymosin Beta-4 Acetate) is a synthetic 43-amino acid peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH) derived from naturally occurring thymosin beta-4, a protein originally isolated from the thymus gland in 1966 and representing 70–80% of beta-thymosin peptides in mammalian cells. Thymosin beta-4 functions as the primary regulator of G-actin cytoskeletal dynamics. The N-terminal acetylation confers resistance to aminopeptidase degradation and enhances metabolic stability. The conserved actin-binding domain at positions 17–23 (¹⁷LKKTETQ²³) mediates high-affinity G-actin sequestration (Kd 0.5–0.7 μM). Supplied as a lyophilized powder for in vitro research, intended strictly for qualified researchers.

Key Research Highlights

Research Area	Key Finding
Alzheimer Disease Research	TMSB4X gene therapy reduced amyloid plaques, decreased glial activation, alleviated neuronal hyperexcitability in 5xFAD mice (Choate et al., 2025, Nat Commun)
Pulmonary Fibrosis Research	Aerosol Tβ4 alleviated bleomycin-induced pulmonary fibrosis via TGF-β1 pathway suppression (Li et al., 2024)
Angiogenesis Research	Direct VEGF upregulation via Wnt/β-catenin/Lef-1; significantly increased MMP-2/VEGF in Tβ4-overexpressing mice (Zhang et al., 2023; Dou et al., 2021)
Anti-Fibrotic Activity	Reduced TGF-β1, TGFβR II, Smad2, Smad3 in liver fibrosis; more organized collagen alignment vs. controls (Nature Sci Rep, 2017)

Research Applications

Actin cytoskeletal dynamics and cell motility research
Angiogenesis and vascular biology (VEGF/Wnt/β-catenin signaling)
Cardiovascular tissue and cardiac biology research
Neuroprotection research (traumatic brain injury, neurodegeneration models)
Pulmonary fibrosis research (TGF-β1 pathway, JAK2/STAT3 inhibition)
Hepatic fibrosis and stellate cell biology
Anti-inflammatory and NF-κB pathway research
Corneal and ophthalmic research
Tissue engineering and stem cell biology

Research Use Only. This product is supplied for in vitro laboratory investigation by qualified researchers. Not for human or veterinary consumption, diagnosis, treatment, prevention, or cure of any condition. Not approved by the FDA for human use.

Customers who bought this item also bought

Semax (10 mg)

ACTH(4-10) Heptapeptide Analogue: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP); ≥98% purity by HPLC; Pro-Gly-Pro C-terminal extension confers enhanced metabolic stability vs. native ACTH(4-10)
Multi-Pathway Neurotrophin Research: BDNF upregulation (1.4× protein, 3× mRNA in hippocampus at 50 μg/kg), serotonergic modulation (180% extracellular 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity
800+ Peer-Reviewed Publications: Neuroprotection, cerebrovascular, neurotrophic factor, and transcriptomic ischemia research; registered pharmaceutical in Russia since 2011

From $33.25